Dr. Herbst on the Impact of Frontline Immunotherapy in Lung Cancer – OncLive
|
Dr. Herbst on the Impact of Frontline Immunotherapy in Lung Cancer
OncLive Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the impact that immunotherapy has had on the frontline treatment of patients with lung cancer. Lung cancer was once a … |
